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Synergism between anti-HER2 monoclonal antibody (trastuzumab) and paclitaxel has been shown in vitro and in vivo. In previous
experiences, weekly administration of trastuzumab and paclitaxel has shown significant activity in metastatic breast cancer. In this
phase II study, we evaluated the activity and the toxicity of this weekly regimen in anthracycline- and taxane-pretreated patients with
HER2-overexpressing metastatic breast cancer. Between November 1999 and July 2001, 25 patients were treated with trastuzumab
(4mgkg
 1 i.v. loading dose followed by 2mgkg
 1 i.v.week
 1) and paclitaxel (60–90mgm
 2h
 1 i.v. infusionweek
 1). The
treatment was planned to continue until disease progression or prohibitive toxicity; in patients with responsive or stable disease, after
6 months of therapy, the decision to stop paclitaxel while continuing weekly trastuzumab was left to the physicians’ judgement. At the
median follow-up of 19.6 months (range 9.2–38.1), all patients are evaluable for response and toxicity. We obtained four (16%)
complete responses (CR), 10 (40%) partial responses (PR), four (16%) stable diseases and seven (28%) disease progressions. The
response rate (CRþPR) was 56% (95% CI, 36.5–75.5%). The median duration of response was 10.4 months (range 4.1–24.2þ).
Median time to progression was 8.6 months (range 2.5–24.2þ). The toxicity was mild; five patients experienced fever and chills
during the first infusion of trastuzumab (20%); leukopenia grade 2 was recorded in one patient (4%). Two patients (8%) came off
study for grade 3 cardiotoxicity (after 9 and 17 weeks of treatment, respectively): both had already received anthracyclines and
taxanes. Onycholysis grade 2 was observed in five patients (20%). These results confirm that weekly administration of trastuzumab
and paclitaxel is active in anthracycline- and taxane-pretreated metastatic breast cancer patients HER2-overexpressing. Since cardiac
disfunctions grade 3 were observed (8%), we recommend that cardiac function should be monitored in these patients.
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In the past decade, molecular and genetic changes that cause
malignant transformation were identified and these abnormalities
can be targets for anticancer treatment. The human epidermal
growth factor receptor-tyrosine kinase 2 (HER2) gene is amplified
in 25–30% of breast cancers and this amplification causes
overexpression of the encoded protein in 95% of cases (Slamon
et al, 1987). This alteration is associated with more rapid growth of
tumour cells and patients with breast cancer overexpressing HER2
have a worse prognosis (Slamon et al, 1987; Ravdin et al, 1995).
Trastuzumab is a humanised monoclonal antibody with specificity
for the HER2 protein; it binds to the extracellular domain of HER2
and blocks its function in signal transduction. In preclinical
studies trastuzumab inhibited the growth of the HER2-over-
expressing tumour cells. Results of phase II trials provided
evidence that it is safe and clinically active in patients with
HER2 overexpressing metastatic breast cancer, with a response
rate of 12–40% (Baselga et al, 1996; Cobleigh et al, 1999; Vogel
et al, 2002).
Preclinical studies have shown a potentially enhanced anti-
tumour activity when trastuzuamb is combined with traditional
chemotherapeutic agents. In Slamon’s experience, the addition of
trastuzumab to chemotherapy (doxorubicin plus cyclophospha-
mide or three-weekly paclitaxel) was associated with higher
response rates and a longer median survival compared with
chemotherapy alone (Slamon et al, 2001). Although effective, the
combination of doxorubicin-cyclophosphamide and trastuzumab
resulted in a higher percentage of severe cardiac dysfunctions
compared with paclitaxel and monoclonal antibody. This observa-
tion and results of preclinical studies led to the development of
combinations of trastuzumab and other antiblastic drugs, such as
cisplatin (Pegram et al, 1998), vinorelbine (Burstein et al, 2001),
taxotere (Esteva et al, 2002), liposomal doxorubicin (Theodoulou
et al, 2002) or weekly paclitaxel (Seidman et al, 2001).
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lTrastuzumab and weekly administration of paclitaxel in metastatic
breast cancer with HER2 overexpression or normal HER2
expression have been evaluated, with promising results (Seidman
et al, 2001).
In this phase II study, we evaluated the activity and toxicity of
weekly trastuzumab and paclitaxel in HER2-overexpressing meta-
static breast cancer patients, who had received prior therapy with
anthracyclines and taxanes.
PATIENTS AND METHODS
Eligibility
Patients with metastatic, anthracycline- and taxane-pretreated
breast cancer that overexpressed HER2 were considered for
enrolment. Informed consent was obtained from all patients.
The eligibility criteria included a life expectancy Z3 months,
ECOG performance status r2, measurable lesions, adequate liver,
renal and bone function, and normal left-ventricular ejection
fraction (LVEF) measured by echocardiography.
Patients were excluded for active infection, pregnancy or
lactation, significant cardiac disease (New York Heart Association
Functional Class III or IV) or haemorrhagic diathesis, history of
grade 3 or 4 peripheral neuropathy of any aetiology, osteoblastic
bone metastases or pleural effusion or ascites as the only evidence
of disease, a second type of primary cancer (except for carcinoma
in situ of the cervix or nonmelanoma skin cancer), previous
therapy with a monoclonal or polyclonal antibody or concomitant
use of any investigational agent.
Tumour expression of HER2 was determined by immunohisto-
chemical (IHC) analysis using a monoclonal antibody CB11
(Biogenex, San Ramon, CA, dilution 1:10, in 19 patients) or a
polyclonal antibody DA485 (DAKO Corp., dilution 1:100, in six
patients) on paraffin-embedded, formalin-fixed tumour specimens
collected either at the time of initial biopsy or at recurrence. In
order to be eligible for the study, all tumours had to have a weak to
strong membrane staining in Z60% of the neoplastic cells.
Subsequently, we have reanalysed our data utilising the HercepT-
est scoring system from 0 to 3þ according to standard criteria, as
follows: 0, if membrane staining was absent or present in less than
10% of tumour cells; 1þ, if membrane positivity was weak and
incomplete in more than 10% of tumour cells; 2þ, if membrane
positivity was moderate and complete in more than 10% of tumour
cells; 3þ, if more than 10% of tumour cells showed strong and
complete membrane staining. Slides from 21 patients were
reanalysed; in the other four patients, the slides for review were
not available.
Treatment
Before starting therapy, all patients had a complete staging that
included history and physical examinations, blood count and
chemistry profile, chest X-ray or CT, bone scan, liver ultrasound or
CT. A bone X-ray or MRI survey was performed if abnormal
uptake areas were observed in the bone scan. ECG and
echocardiography were performed at baseline and then every 3
months.
Trastuzumab was administered intravenously (i.v.) in the
outpatient setting at a loading dose of 4mgkg
 1 on day 0,
followed by weekly administration of 2mgkg
 1. The first infusion
was given over 90min; if the infusion was well tolerated,
subsequent infusions were shortened to 30min. If patients
experienced an infusion syndrome, treatment was stopped and a
supportive treatment was started if necessary (acetaminophen,
dexamethasone, diphenhydramin, H2 antagonist).
Paclitaxel was administered at a dose of 60–90mgm
 2 over 1-h
i.v. infusion. The starting dose was determined on the basis of the
prior treatment (type of antineoplatic drugs, number of previous
chemotherapy regimens and prior toxicities), age and performance
status of the patient. The first dose of paclitaxel was given on day 2
and then weekly on the same day as and after trastuzumab
administration. Premedication consisted of dexamethasone 10mg
i.v., orphenadrine 40mg i.m., ranitidine 100mg i.v. and ondanse-
tron 8mg i.v., all given 30min before the paclitaxel infusion.
Paclitaxel dose was adjusted each week on the day of therapy,
based on haematologic toxicity. Paclitaxel was administered at full
dose if the absolute neutrophil count was 41500cellsml
 1 and/or
platelet count 4100000cellsml
 1. The drug was reduced by 50% if
the absolute neutrophil count was 1499–1000cellsml
 1 and/or the
platelet count 99000–50000cellsml
 1; paclitaxel was omitted if the
absolute neutrophil count was o1000cellsml
 1 and/or the platelet
count o50000cellsml
 1. No dose adjustments for trastuzumab
therapy were considered.
After 6 months of therapy, the treatment was left to the
discretion of physicians. In patients with responsive or stable
disease, the protocol allowed the investigators to continue
paclitaxel and trastuzumab until progression or prohibitive
toxicity, or to stop paclitaxel while continuing trastuzumab. When
disease progression was detected, weekly trastuzumab could be
continued at the dose of 2mgkg
 1 or discontinued at the
physician’s discretion, because the utility of continuing trastuzu-
mab in progressing patients is still uncertain. Additional
antitumour therapy was also permitted upon disease progression.
Tumour response and statistical methods
Response to therapy was assessed every 12 weeks of treatment,
according to the WHO criteria (Miller et al, 1981). Toxicity
evaluation was performed every week and graded according to the
National Cancer Institute Common Toxicity Criteria (NCI-CTC).
The primary end points were tumour response rate and toxicity
of treatment. The secondary end points were duration of response,
time to progression and survival.
Duration of response was defined as the time from the start of
therapy to disease progression. Time to progression (TTP) was
defined as the time from the start of treatment to disease
progression or death (whichever occurred first), and was censored
at the last date of contact for patients whose disease did not
progress. Survival was defined as the time from the start of therapy
to death, and was censored at the date of last contact for patients
who were alive.
Responses, TTP and survival were determined for all eligible
enrolled patients. The time to event end points was estimated by
Kaplan–Meier survival methodology (Kaplan and Meier, 1958).
RESULTS
From November 1999 to July 2001, 25 patients with HER2-
overexpressing metastatic breast cancer and pretreated with
anthracycline-containing regimens entered this phase II trial.
Patient baseline characteristics are listed in Table 1.
A total of 20 patients had already received taxanes (docetaxel or
paclitaxel in combination with other drugs): nine patients received
paclitaxel (six patients in metastatic, one patient in adjuvant and
two patients in neoadjuvant setting) and 11 patients docetaxel (all
in metastatic setting). In metastatic setting, the median interval
from prior taxane to enrollment in the study was 6.5 months
(range 5–52 months) for paclitaxel and 5 months (range 2–21
months) for docetaxel; objective responses were seen in 33% of
patients who received paclitaxel and in 27% of patients who
received docetaxel, respectively. The time to recurrence from prior
paclitaxel therapy was 10 and 30 months for the two patients
treated in neoadjuvant setting and 10 months for the only patient
who received paclitaxel in adjuvant setting.
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lIn all, 15 patients (60%) were postmenopausal and 22 (88%) had
visceral involvement. A total of 19 patients (72%) had received
chemotherapy for advanced disease.
A total of 528 weekly trastuzumab and paclitaxel infusions were
delivered with a median of 24 weekly treatments per patient (range
6–45). The paclitaxel median delivered dose was
70mgm
 2week
 1 (range 60–90mgm
 2).
All patients were assessable for response. The overall response
rate was 56% (95% CI, 36.5–75.5%) with four complete responses
(16%) and 10 partial responses (40%). Stable disease was observed
in 16% of patients. Only seven patients had progression disease
(28%). A response was obtained in 11 of 20 patients pretreated
with taxanes (55%). The median response duration was 10.4
months (range 4.1–24.2þ).
In the four patients with complete response, the weekly
monotherapy with trastuzumab was continued after 25, 29, 37
and 45 doses of trastuzumab and paclitaxel. In six out of 10
patients who had obtained a partial response after 6 months of
trastuzumab and paclitaxel, trastuzumab was continued as
monotherapy or in association with other antineoplastic drugs
when disease progression was detected. In one out of four patients
with stable disease, trastuzumab was continued for a total of 69
weekly doses at the date of this analysis.
When the herceptest scoring was applied, 67% of tumours were
HER2 3þ, 29% HER2 2þ and 5% HER2 1þ. This retrospective
analysis was performed in 11 out of 14 responsive patients: the
tumours were 3þ in 10 responsive patients (91%) and 2þ in one
patient (9%).
At the median follow-up of 19.6 months (range 9.2–38.1), the
median time to progression was 8.6 months (range 2.5–24.2þ);
only nine patients died and the median overall survival has not
been reached.
In six out of 14 responsive patients (42.8%), the relapses
occurred in the central nervous system (CNS) and in five patients
(83.3%) the brain metastases represented the only site of
progressive disease, while complete or partial response was
maintained in the other disease sites. These patients continued
trastuzumab therapy during and after whole-brain irradiation.
Toxicity
Treatment was generally well tolerated (Tables 2, 3). Hypersensi-
tivity reactions including fever and chills were recorded in five
patients during the first infusion of trastuzumab, and in one
patient it was associated with symptomatic bronchospasm.
Leukopenia grade 2 was observed in one patient (4%) and
anaemia grade 2 in two patients (8%). Peripheral neuropathy grade
1–2 affected nine patients (36%); onycholysis grade 2 was
observed in five patients (20%). Alopecia grade 2 was reported
in 43% of 14 assessable patients.
Grade 3 cardiotoxicity was manifested in two patients (8%) after
9 and 17 weeks of treatment, respectively. These patients
developed symptomatic congestive heart failure with decline in
left ventricular ejection fraction in one patient (EF¼35%). Cardiac
function improved with standard medical therapy, but the patients
came off study. Both had already received anthracyclines and
taxanes for metastatic disease.
Table 1 Patient characterists (n¼25)
Patients
Characteristic No. %
Median age (range) 43 years (29–64)
Median ECOG PS (range) 0 (0–1)
Receptor status
ER and PgR negative 13 52
ER and/or PgR positive 11 44
Unknown 1 4
No. of metastatic sites
13 1 2
21 4 5 6
Z38 3 2
Metastatic site
Soft tissue 2 8
Bone 1 4
Visceral 22 88
Prior therapy
Adjuvant chemotherapy 23 92
Metastatic chemotherapy 19 76
One prior regimen 7 28
Z2 prior regimens 12 48
Prior anthracyclines 25 100
Prior taxanes 20 80
Bone marrow or stem cells transplantation 2 8
Disease-free interval
0–12 months 6 24
13–24 months 7 28
424 months 12 48
Table 2 Toxicity-NCI criteria (25 assessable patients)
Events, n (%)
Grade 1 Grade 2 Grade 3 Grade 4
Haematologic
Anaemia 2 (8%) 2 (8%) — —
Leukopenia 1 (4%) 1 (4 %) — —
Thrombocytopenia — — — —
Gastrointestinal
Nausea 3 (12 %) — — —
Vomiting 2 (8%) — — —
Stomatitis 1 (4%) 2 (8%) — —
Diarrhoea — — — —
Alopecia (assessable in 14 pts) 6 (43%) 5 (36%) — —
Neurosensory 6 (24%) 3 (12%) — —
Cardiovascular — — 2 (8%) —
Myalgia 3 (12%) — — —
Asthenia 3 (12%) — — —
Hypersensitivity reaction 2 (8%) 2 (8%) 1 (4%) —
Onycholysis — 5 (20%) —
Table 3 Response to therapy
Patients
Response No. %
Overall response (CR+PR) 14 56
*
Complete response 4 16
Partial response 10 40
Stable disease 4 16
Progressive disease 7 28
*95% CI, 36.5–75.5%.
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The results of this phase II study suggest that treatment with
weekly trastuzumab and paclitaxel is very active in patients with
HER2-overexpressing metastatic breast cancer, who have pre-
viously received anthracycline-based regimens.
We obtained an overall response rate of 56%, comparable with
that reported in HER2 normal and HER2-overexpressing pre-
treated patients (56.8%) utilising weekly trastuzumab and
paclitaxel (Seidman et al, 2001). Similar results (62% of objective
responses) were also obtained with the same combination
administered as first-line in 35 patients with HER2-overexpressing
metastatic breast cancer (Fountzilas et al, 2001). However, in our
study, the majority of patients (76%) were pretreated with
chemotherapy for advanced disease and 48% of patients had
received X2 prior regimens.
Interestingly, 11 out of 20 patients (55%) pretreated with taxanes
responded to weekly trastuzumab and paclitaxel. Overexpression
of HER2 blocks paclitaxel-induced apoptosis by upregulation of a
cycline-dependent kinase inhibitor (p21), which inhibits p34
cdc2
kinase (Yu et al, 1998). Probably, trastuzumab, by regulating
HER2, inactivates the p21 and restores sensitivity to paclitaxel-
induced apoptosis.
In our experience, the median response duration was 10.4
months (range 4.1–24.2þ); at the median follow-up of 19.6
months (range 9.2–38.1), the median time to progression was 8.6
months (range 2.5–24.2þ) and median overall survival had not
been reached. This could probably be due to the fact that, after 6
months of therapy, treatment with trastuzumab was continued in
11 patients, and this could have positively affected the survival.
In the present study, no specific method of IHC was
recommended to estimate HER2 overexpression. Two antibodies
(monoclonal and policlonal) were used. Due to the small number
of patients, it is impossible to compare the responsiveness
according to each method. For the trial, we have considered
tumours with a weak to strong membrane staining in Z60% of the
neoplastic cells, because accumulating evidence suggests that the
degree of HER2 overexpression is important for prediction of
response to trastuzumab. When the herceptest scoring system was
applied, the tumours resulted IHC 3þ in 91% of responsive
patients whose tissue samples were available, and IHC 2þ in 9%.
These results reflect the problem of the more appropriate methods
to evaluate the HER2 status.
In our trial, the haematological, gastrointestinal and neurologi-
cal toxicities were mild. Since we had decided to include in our
trial anthracycline- and taxane-pretreated patients, we planned a
dose reduction schema for haematologic toxicity for paclitaxel.
Actually, we observed only grade 1 and 2 haematologic toxicity in a
few patients, and we think that our dose reduction schema is
excessive and unnecessary. The neurotoxicity was also very mild
(only grade 1 and 2). The median dose of paclitaxel in our
experience was 70mgm
 2week
 1, lower than that used by
Seidamn et al (91mgm
 2week
 1) (Seidman et al, 2001). The
difference could explain the absence of grade 3–4 neurotoxicity in
our patients, pretreated also by taxanes. We observed grade 3
cardiotoxicity in two out of 25 patients (8%) pretreated with
anthracyclines, comparable with the results reported by other
authors (Seidman et al, 2002). Both our patients had received a
cumulative dose of epidoxorubicin 4400mgm
 2, which is the
only risk factor identified for cardiotoxicity, besides the con-
comitant use of anthracycline and advanced age (Slamon et al,
2001); these two patients were also pretreated with taxanes for
metastatic disease. To date, we do not know the true incidence of
trastuzumab cardiac toxicity when it is given alone or with other
antineoplastic drugs; the ongoing clinical trials, with careful
cardiac monitoring, are likely to give us more accurate information
Speyer, 2002. The mechanism of trastuzumab cardiotoxicity is
unknown (Ewer et al, 1999; Keefe et al, 2002; Seidman et al, 2002)
and the pathogenesis and histologic changes responsible for
trastuzumab-associated cardiotoxicity are currently under inves-
tigation. Understanding the mechanisms of the trastuzumab-
associated cardiotoxicity is important to provide strategies for the
prevention or identification of patients at risk for cardiac
complications. Given the poor prognosis of patients with HER2-
overexpressing metastatic breast cancer, the cardiotoxicity of
trastuzumab must be weighed against its potential clinical benefit.
As these results confirm that weekly administration of trastuzu-
mab and paclitaxel is active in anthracycline-pretreated metastatic
breast cancer HER2-overexpressing patients (RO¼56%), and in
the subset of patients also pretreated with taxanes (RO¼55%), this
risk of cardiac dysfunction (8%) can be considered acceptable.
Anyway, we recommend that cardiac function should be
established at baseline and monitored regularly (every 3–4
months) during treatment by physical examination and measure-
ment of the left-ventricular ejection fraction (by MUGA scan or
echocardiography). This is very important because some patients
who develop cardiotoxicity while receiving treatment with
trastuzumab recover systolic function with medical standard
therapy, and are able to continue trastuzumab therapy.
We observed a high incidence of relapse (42.8%) in CNS: in five
patients (83.3%), the brain metastases represented the only site of
progressive disease, while complete or partial response was
maintained in the other disease sites. The incidence of this
complication has also been reported by other authors (Lower et al,
2001). The high incidence of developing CNS metastases may be
increased in these patients because of their prolonged survival.
Moreover, during intravenous trastuzumab treatment, only a
minimal amount of monoclonal antibody penetrates the cere-
brospinal fluid (CSF) (Pestalozzi et al, 2000) as well as taxanes.
In conclusion, the present trial demonstrates that weekly
trastuzumab and paclitaxel is a safe and effective treatment in
anthracycline- and taxane-pretreated metastatic breast cancer
patients. The addition of trastuzumab to chemotherapy positively
affects the natural history of the HER2-overexpressing breast
cancer, though many questions about the best dose and schedule
(weekly or 3-weekly) of trastuzumab (Gelmon et al, 2001;
Carbonell et al, 2002), the best combination and the optimal
duration of therapy with trastuzumab need to be addressed. There
is no information about a comparison of trastuzumab and
chemotherapy vs trastuzumab as single-agent therapy, followed
by chemotherapy at the time of progression. To date, the combined
approach is the only one that has shown a survival gain compared
with chemotherapy alone (Slamon et al, 2001), but the sequential
approach would be more cost-effective (early identification of
patients who do not benefit from trastuzumab) and could delay, in
the trastuzumab-responsive patients, the side effects related to
chemotherapy (Burris et al, 2000).
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